Such heterogeneity could impact the clinical interpretation of diagnostic biopsies and may obscure reasons for nonresponse to ALK inhibitor therapy in patients in whom the majority of the tumour cells do not contain activating ALK mutations54. Here, ALK is linked to neoplasm.